TY - JOUR
T1 - The effects of extended evaluation on depressive symptoms in children and adolescents
AU - Rintelmann, Jeanne W.
AU - Emslie, Graham J.
AU - Rush, A. John
AU - Varghese, Thomas
AU - Gullion, Christina M.
AU - Kowatch, Robert A.
AU - Hughes, Carroll W.
N1 - Funding Information:
The authors are grateful to David Savage for secretarial assistance, Tom Carmody, Jeanne Nightingale for their editoral assistancea nd Kenneth 2. Altshuler, M.D., Stanton Sharp Distinguished Chair and Professor, Departmento f Psychiatry, for administrative support. This study was supportedi n part by grants from the National Institute of Mental Health to G.E. Emslie (MH-39188) and the Department of Psychiatry, University of Texas Southwest-em Medical Center at Dallas (MH-41115), by Eli Lilly and Company, and the Sara M. and Charles E. Seay Center for Brain and Applied Research in Psychiatric Illness.
PY - 1996/11/25
Y1 - 1996/11/25
N2 - A sample of 137 child and adolescent outpatients with major depressive disorder were examined to identify baseline clinical characteristics that predicted symptom severity at the end of a 3-week evaluation period and to determine whether change in symptom severity between week 1 and week 2 predicted symptom severity at week three. Subjects underwent three consecutive weekly evaluations prior to being considered for entry into a double-blind, placebo-controlled treatment trial of fluoxetine, Results indicated that the combination of age, social functioning, family history, Children's Depressive Rating Scale-Revised (CDRS-R) (Poznanski et al, (1985) Psychopharmacol. Bull. 21, 979-989) total score at visit one, and percent change in symptom severity between visit one and visit two were predictors of symptom severity at visit three. These findings suggest that (1) subjects should not be excluded from randomized controlled clinical treatment trials based solely on improvement of symptom severity between visits and (2) an extended evaluation period is warranted, especially for adolescents whose symptom severity tends to fluctuate from week to week.
AB - A sample of 137 child and adolescent outpatients with major depressive disorder were examined to identify baseline clinical characteristics that predicted symptom severity at the end of a 3-week evaluation period and to determine whether change in symptom severity between week 1 and week 2 predicted symptom severity at week three. Subjects underwent three consecutive weekly evaluations prior to being considered for entry into a double-blind, placebo-controlled treatment trial of fluoxetine, Results indicated that the combination of age, social functioning, family history, Children's Depressive Rating Scale-Revised (CDRS-R) (Poznanski et al, (1985) Psychopharmacol. Bull. 21, 979-989) total score at visit one, and percent change in symptom severity between visit one and visit two were predictors of symptom severity at visit three. These findings suggest that (1) subjects should not be excluded from randomized controlled clinical treatment trials based solely on improvement of symptom severity between visits and (2) an extended evaluation period is warranted, especially for adolescents whose symptom severity tends to fluctuate from week to week.
KW - Adolescent
KW - Child
KW - Extended evaluation
KW - Major depressive disorder
KW - Predicting response
UR - http://www.scopus.com/inward/record.url?scp=0030602263&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030602263&partnerID=8YFLogxK
U2 - 10.1016/S0165-0327(96)00084-5
DO - 10.1016/S0165-0327(96)00084-5
M3 - Article
C2 - 8961043
AN - SCOPUS:0030602263
SN - 0165-0327
VL - 41
SP - 149
EP - 156
JO - Journal of affective disorders
JF - Journal of affective disorders
IS - 2
ER -